Finding accredited CPD
Due to the growing application of CAR-T cell therapy in the treatment of multiple myeloma, an expert panel of haematologists across Australia have developed a consensus-based recommendation to help guide physicians.
This review provides a summary of their recommendations for patient referral, screening, selection, prioritisation, treatments requiring wash-out, bridging therapy, lymphodepletion, as well as infusion, and post-infusion monitoring and management.
Independent commentary for the review has been provided by Dr Christian Bryant, a Consultant Haematologist at the Institute of Haematology, Royal Prince Alfred Hospital, Sydney NSW, a Senior Lecturer in Medicine at The University of Sydney, co-relative science lead for the ALLG Myeloma Working Party and a member of the Myeloma Scientific and Advisory Committee.
This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide.
Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.
*Medical Board of Australia’s (MBA)’s revised Registration Standard: Continuing professional development (the Standard)
